Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Proteomic resolution of the MASLD cardiometabolic spectrum identifies sex-driven endotypes and predicts systemic mortality.
Clinical takeawayNo clinical action yet: a proteomic score derived from a large cohort study, not yet validated for clinical use in individual patients.
What it foundA four-protein score (PS4) significantly outperformed established non-invasive scores in predicting all-cause mortality in MASLD patients, accounting for 10-20% of the effect of phenotypic class on mortality.
ContextChallenges current liver-centric prognostic models by identifying systemic proteomic markers linked to mortality in MASLD, highlighting sex-driven differences in disease severity.
Emergingsuggested applicable standard· AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674.
Decision at stakeidentifying high-risk MASLD subgroups for mortality prediction
AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674. · reviewed 2026-07-21 ↗Statins are safe and recommended in MASLD/MASH and compensated cirrhosis when indicated for cardiovascular risk reduction. Start per standard CV risk-based criteria with baseline LFTs; routine ALT monitoring on statin is not required and pre-existing transaminitis is not a contraindication. Hold or reduce only for clinically significant ALT elevation, severe muscle symptoms, or decompensated cirrhosis on an individualized basis.
Diambra L … Pirola CJ · Gut · IF 24.6 · PubMed ↗